Cargando…

The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates

Atrial fibrillation (AF) is the most common sustained arrhythmia in the population and is associated with a significant clinical and economic burden. Rigorous assessment of the presence and degree of an atrial arrhythmic substrate is essential for determining treatment options, predicting long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunha, Pedro Silva, Laranjo, Sérgio, Heijman, Jordi, Oliveira, Mário Martins
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289204/
https://www.ncbi.nlm.nih.gov/pubmed/35859594
http://dx.doi.org/10.3389/fcvm.2022.879984
_version_ 1784748612183392256
author Cunha, Pedro Silva
Laranjo, Sérgio
Heijman, Jordi
Oliveira, Mário Martins
author_facet Cunha, Pedro Silva
Laranjo, Sérgio
Heijman, Jordi
Oliveira, Mário Martins
author_sort Cunha, Pedro Silva
collection PubMed
description Atrial fibrillation (AF) is the most common sustained arrhythmia in the population and is associated with a significant clinical and economic burden. Rigorous assessment of the presence and degree of an atrial arrhythmic substrate is essential for determining treatment options, predicting long-term success after catheter ablation, and as a substrate critical in the pathophysiology of atrial thrombogenesis. Catheter ablation of AF has developed into an essential rhythm-control strategy. Nowadays is one of the most common cardiac ablation procedures performed worldwide, with its success inversely related to the extent of atrial structural disease. Although atrial substrate evaluation remains complex, several diagnostic resources allow for a more comprehensive assessment and quantification of the extent of left atrial structural remodeling and the presence of atrial fibrosis. In this review, we summarize the current knowledge on the pathophysiology, etiology, and electrophysiological aspects of atrial substrates promoting the development of AF. We also describe the risk factors for its development and how to diagnose its presence using imaging, electrocardiograms, and electroanatomic voltage mapping. Finally, we discuss recent data regarding fibrosis biomarkers that could help diagnose atrial fibrotic substrates.
format Online
Article
Text
id pubmed-9289204
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92892042022-07-19 The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates Cunha, Pedro Silva Laranjo, Sérgio Heijman, Jordi Oliveira, Mário Martins Front Cardiovasc Med Cardiovascular Medicine Atrial fibrillation (AF) is the most common sustained arrhythmia in the population and is associated with a significant clinical and economic burden. Rigorous assessment of the presence and degree of an atrial arrhythmic substrate is essential for determining treatment options, predicting long-term success after catheter ablation, and as a substrate critical in the pathophysiology of atrial thrombogenesis. Catheter ablation of AF has developed into an essential rhythm-control strategy. Nowadays is one of the most common cardiac ablation procedures performed worldwide, with its success inversely related to the extent of atrial structural disease. Although atrial substrate evaluation remains complex, several diagnostic resources allow for a more comprehensive assessment and quantification of the extent of left atrial structural remodeling and the presence of atrial fibrosis. In this review, we summarize the current knowledge on the pathophysiology, etiology, and electrophysiological aspects of atrial substrates promoting the development of AF. We also describe the risk factors for its development and how to diagnose its presence using imaging, electrocardiograms, and electroanatomic voltage mapping. Finally, we discuss recent data regarding fibrosis biomarkers that could help diagnose atrial fibrotic substrates. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9289204/ /pubmed/35859594 http://dx.doi.org/10.3389/fcvm.2022.879984 Text en Copyright © 2022 Cunha, Laranjo, Heijman and Oliveira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Cunha, Pedro Silva
Laranjo, Sérgio
Heijman, Jordi
Oliveira, Mário Martins
The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
title The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
title_full The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
title_fullStr The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
title_full_unstemmed The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
title_short The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
title_sort atrium in atrial fibrillation – a clinical review on how to manage atrial fibrotic substrates
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289204/
https://www.ncbi.nlm.nih.gov/pubmed/35859594
http://dx.doi.org/10.3389/fcvm.2022.879984
work_keys_str_mv AT cunhapedrosilva theatriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates
AT laranjosergio theatriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates
AT heijmanjordi theatriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates
AT oliveiramariomartins theatriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates
AT cunhapedrosilva atriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates
AT laranjosergio atriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates
AT heijmanjordi atriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates
AT oliveiramariomartins atriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates